{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:55:55Z","timestamp":1792425355670,"version":"4.5.0"},"reference-count":107,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,8,5]]},"abstract":"<jats:sec id=\"ab-jrv250013-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Uveitis is characterized by inflammation of the uvea\u2014the middle portion of the eye composed of the iris, ciliary body, and choroid\u2014causing eye redness, pain, photophobia, floaters, and blurred vision. Untreated uveitis may cause cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250013-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      Uveitis predominantly affects individuals aged 20 to 50 years. Anterior uveitis affects the iris and ciliary body (41%-60% of cases); intermediate uveitis affects the pars plana (attachment point of vitreous humor) and peripheral retina (9%-15%); posterior uveitis involves the choroid and\/or retina (17%-23%); and panuveitis involves all uveal layers (7%-32%). Uveitis is classified as noninfectious or infectious, with toxoplasmosis, herpes, tuberculosis, and HIV comprising 11% to 21% of infectious cases in high-income countries and 50% in low- and middle-income countries. Incidence and prevalence of uveitis are influenced by genetic factors (eg, human leukocyte antigen\u2013B27), environmental factors (eg, air pollution), and infection rates. In the US and Europe, 27% to 51% of uveitis cases are idiopathic, and 37% to 49% are associated with systemic disease, such as axial spondyloarthritis. Treatment goals are to induce and maintain remission while minimizing corticosteroid use to reduce corticosteroid-related adverse effects. Infectious uveitis requires systemic antimicrobial treatment. Active inflammatory disorders associated with uveitis should be treated by the appropriate specialist (eg, rheumatologist). Treatment for uveitis depends on subtype; anterior uveitis is treated with topical corticosteroids, and mild intermediate uveitis may be monitored without initial treatment. Patients with moderate to severe intermediate uveitis, posterior uveitis, and panuveitis are at high risk of sight-threatening complications and require systemic and\/or intravitreal corticosteroids and immunosuppressive agents. For posterior uveitis, first-line therapy with disease-modifying antirheumatic drugs such as methotrexate achieved remission of inflammation in 52.1% (95% CI, 38.6%-67.1%) of patients, and mycophenolate mofetil controlled inflammation in 70.9% (95% CI, 57.1%-83.5%). In patients who do not improve or worsen with first-line therapy, adalimumab extended time to treatment failure to 24 weeks vs 13 weeks with placebo and reduced frequency of treatment failure from 78.5% to 54.5% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250013-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Uveitis is characterized by inflammation of the uvea and primarily affects adults aged 20 to 50 years. For noninfectious anterior uveitis, corticosteroid eyedrops are first-line treatment. For posterior noninfectious uveitis, disease-modifying antirheumatic drugs are first-line therapy; biologics such as adalimumab are second-line treatment for patients with inflammation refractory to treatment. Uveitis caused by systemic infection should be treated with antimicrobials, and local or systemic steroids may be used depending on the severity of uveitis and the specific microorganism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.4358","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:31:07Z","timestamp":1748431867000},"page":"419","source":"Crossref","is-referenced-by-count":95,"title":["Uveitis in Adults"],"prefix":"10.1001","volume":"334","author":[{"given":"Panayiotis","family":"Maghsoudlou","sequence":"first","affiliation":[{"name":"Academic Unit of Ophthalmology, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"},{"name":"Regional Ocular Inflammatory Service, Bristol Eye Hospital, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Epps","sequence":"additional","affiliation":[{"name":"Regional Ocular Inflammatory Service, Bristol Eye Hospital, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Guly","sequence":"additional","affiliation":[{"name":"Regional Ocular Inflammatory Service, Bristol Eye Hospital, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Dick","sequence":"additional","affiliation":[{"name":"Academic Unit of Ophthalmology, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"},{"name":"School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom"},{"name":"UCL Institute of Ophthalmology, London, United Kingdom"},{"name":"National Institute for Health and Care Research Moorfields Biomedical Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"jrv250013r1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.5301\/ejo.5000278","article-title":"Review on the worldwide epidemiology of uveitis.","volume":"23","author":"Miserocchi","year":"2013","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"jrv250013r2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ophtha.2015.10.028","article-title":"Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis.","volume":"123","author":"Dick","year":"2016","journal-title":"Ophthalmology"},{"issue":"5","key":"jrv250013r3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10792-010-9359-y","article-title":"The causes of uveitis in a referral centre of Northern Italy.","volume":"30","author":"Cimino","year":"2010","journal-title":"Int Ophthalmol"},{"issue":"1-2","key":"jrv250013r4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/08820538.2021.1885721","article-title":"Epidemiology of uveitis in a tertiary care centre in Portugal.","volume":"36","author":"Hermann","year":"2021","journal-title":"Semin Ophthalmol"},{"issue":"9","key":"jrv250013r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102351","article-title":"Uveitis: Autoimmunity\u2026 and beyond.","volume":"18","author":"Bertrand","year":"2019","journal-title":"Autoimmun Rev"},{"key":"jrv250013r6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2147\/OPTH.S80972","article-title":"Epidemiology of uveitis in the mid-Atlantic United States.","volume":"9","author":"Bajwa","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"jrv250013r7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/aos.14130","article-title":"Epidemiology of uveitis in a region of southern Sweden.","volume":"98","author":"Bro","year":"2020","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"jrv250013r8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/09273948.2016.1196713","article-title":"A focus on the epidemiology of uveitis.","volume":"26","author":"Tsirouki","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"jrv250013r9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.4103\/ijo.IJO_1122_21","article-title":"LV Prasad Eye Institute EyeSmart electronic medical record-based analytics of big data: LEAD-Uveitis Report 1: demographics and clinical features of uveitis in a multi-tier hospital based network in Southern India.","volume":"70","author":"Tyagi","year":"2022","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"jrv250013r10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/112067210101100110","article-title":"Uveitis in HIV-infected patients.","volume":"11","author":"Mwanza","year":"2001","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"jrv250013r11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1750-1172-7-57","article-title":"Uveitis\u2014a rare disease often associated with systemic diseases and infections\u2014a systematic review of 2619 patients.","volume":"7","author":"Barisani-Asenbauer","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"jrv250013r12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1869-5760-3-43","article-title":"Drug-induced uveitis.","volume":"3","author":"London","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"8","key":"jrv250013r13","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1136\/bjophthalmol-2019-315280","article-title":"Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open angle glaucoma.","volume":"104","author":"Hu","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"jrv250013r14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18502\/jovr.v16i1.8254","article-title":"Medication-induced uveitis: an update.","volume":"16","author":"Iqbal","year":"2021","journal-title":"J Ophthalmic Vis Res"},{"issue":"2","key":"jrv250013r15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0161-6420(00)00499-1","article-title":"Uveitis masquerade syndromes.","volume":"108","author":"Rothova","year":"2001","journal-title":"Ophthalmology"},{"issue":"5","key":"jrv250013r16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000518496","article-title":"Immune-mediated uveitis and lifestyle factors: a review.","volume":"64","author":"Guo","year":"2021","journal-title":"Ophthalmic Res"},{"key":"jrv250013r17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.613893","article-title":"Association between air pollution and the risk of uveitis: a nationwide, population-based cohort study.","volume":"12","author":"Bai","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"jrv250013r18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/bjo.76.3.137","article-title":"Uveitis and systemic disease.","volume":"76","author":"Rothova","year":"1992","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"jrv250013r19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ajo.2013.03.027","article-title":"Approach to the diagnosis of the uveitides.","volume":"156","author":"Jabs","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"jrv250013r20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1076\/ocii.10.4.263.15592","article-title":"Uveitis: a global perspective.","volume":"10","author":"Chang","year":"2002","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"jrv250013r21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1600-0420.1995.tb00040.x","article-title":"Epidemiology of endogenous uveitis in south-western Finland.","volume":"73","author":"Saari","year":"1995","journal-title":"Acta Ophthalmol Scand"},{"issue":"11","key":"jrv250013r22","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","article-title":"Prevalence of noninfectious uveitis in the United States: a claims-based analysis.","volume":"134","author":"Thorne","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"jrv250013r23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/IIO.0000000000000072","article-title":"The role of sex in uveitis and ocular inflammation.","volume":"55","author":"Yeung","year":"2015","journal-title":"Int Ophthalmol Clin"},{"key":"jrv250013r24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/09273948.2018.1489061","article-title":"The Collaborative Ocular Tuberculosis Study (COTS)-1: a multinational description of the spectrum of choroidal involvement in 245 patients with tubercular uveitis.","volume":"28","author":"Agrawal","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"jrv250013r25","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.survophthal.2021.10.001","article-title":"Global prevalence and clinical outcomes of tubercular uveitis: a systematic review and meta-analysis.","volume":"67","author":"Alli","year":"2022","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"jrv250013r26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4103\/0301-4738.45506","article-title":"Pattern of uveitis in North East India: a tertiary eye care center study.","volume":"57","author":"Das","year":"2009","journal-title":"Indian J Ophthalmol"},{"issue":"4","key":"jrv250013r27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1076\/ocii.11.4.277.18260","article-title":"Changing patterns of intraocular inflammatory disease in Japan.","volume":"11","author":"Wakabayashi","year":"2003","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"jrv250013r28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3906\/sag-1302-132","article-title":"Epidemiology of uveitis in a referral hospital in Turkey.","volume":"44","author":"\u00c7akar \u00d6zdal","year":"2014","journal-title":"Turk J Med Sci"},{"key":"jrv250013r29","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2147\/OPTH.S89428","article-title":"Intermediate uveitis, posterior uveitis, and panuveitis in the Mid-Atlantic USA.","volume":"9","author":"Engelhard","year":"2015","journal-title":"Clinical Ophthalmol"},{"issue":"5","key":"jrv250013r30","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/09273948.2022.2067067","article-title":"Changing trends in uveitis in the United Kingdom: 5000 consecutive referrals to a tertiary referral centre.","volume":"31","author":"Jones","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"jrv250013r31","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/ard.2007.075754","article-title":"Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review.","volume":"67","author":"Zeboulon","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"jrv250013r32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/bjophthalmol-2014-305518","article-title":"Characterisation of uveitis in association with multiple sclerosis.","volume":"99","author":"Messenger","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"jrv250013r33","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/09273948.2016.1175642","article-title":"Review for disease of the year: epidemiology of HLA-B27 associated ocular disorders.","volume":"24","author":"Kopplin","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"jrv250013r34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0002-9394(14)70533-1","article-title":"Clinical features and associated systemic diseases of HLA-B27 uveitis.","volume":"121","author":"Tay-Kearney","year":"1996","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"jrv250013r35","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s00415-006-0084-4","article-title":"Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy.","volume":"253","author":"Laroni","year":"2006","journal-title":"J Neurol"},{"issue":"5","key":"jrv250013r36","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1442-9071.2009.02082.x","article-title":"Clinical patterns of uveitis in two ophthalmology centres in Bogota, Colombia.","volume":"37","author":"de-la-Torre","year":"2009","journal-title":"Clin Exp Ophthalmol"},{"key":"jrv250013r37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2025.2452193","article-title":"Epidemiological characterization of uveitis in Japan: a systematic review.","author":"Liba","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"jrv250013r38","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/archopht.1996.01100130585016","article-title":"Referral patterns of uveitis in a tertiary eye care center.","volume":"114","author":"Rodriguez","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"jrv250013r39","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.survophthal.2005.04.003","article-title":"Acute anterior uveitis and HLA-B27.","volume":"50","author":"Chang","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"jrv250013r40","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20951733","article-title":"Uveitis in spondyloarthritis.","volume":"12","author":"Rademacher","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"jrv250013r41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3109\/09273948.2013.855799","article-title":"The Manchester Uveitis Clinic: the first 3000 patients\u2014epidemiology and casemix.","volume":"23","author":"Jones","year":"2015","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"jrv250013r42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273940801899822","article-title":"International Uveitis Study Group (IUSG): clinical classification of uveitis.","volume":"16","author":"Deschenes","year":"2008","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"jrv250013r43","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.ajo.2013.11.002","article-title":"Neoplastic masquerade syndromes in patients with uveitis.","volume":"157","author":"Grange","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"jrv250013r44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/eye.2011.255","article-title":"Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation.","volume":"26","author":"Lee","year":"2012","journal-title":"Eye (Lond)"},{"key":"jrv250013r45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.623725","article-title":"Uveitis: molecular pathogenesis and emerging therapies.","volume":"12","author":"Egwuagu","year":"2021","journal-title":"Front Immunol"},{"issue":"9","key":"jrv250013r46","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis.","volume":"88","author":"Durrani","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"jrv250013r47","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/bjophthalmol-2021-318916","article-title":"Diagnostic value of culture results from aqueous tap versus vitreous tap in cases of bacterial endophthalmitis.","volume":"106","author":"AlBloushi","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"jrv250013r48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1444-0938.2006.00128.x","article-title":"Acute anterior uveitis in primary care.","volume":"90","author":"Gutteridge","year":"2007","journal-title":"Clin Exp Optom"},{"issue":"3","key":"jrv250013r49","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10792-004-5195-2","article-title":"Efficacy and safety of 1% rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis\u2014a randomized triple masked study.","volume":"25","author":"Biswas","year":"2004","journal-title":"Int Ophthalmol"},{"issue":"11","key":"jrv250013r50","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/bjophthalmol-2020-317354","article-title":"Recommendations for the management of ocular sarcoidosis from the International Workshop on Ocular Sarcoidosis.","volume":"105","author":"Takase","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"jrv250013r51","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","article-title":"Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) trial.","volume":"126","author":"Thorne","year":"2019","journal-title":"Ophthalmology"},{"issue":"7","key":"jrv250013r52","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial.","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"issue":"4","key":"jrv250013r53","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"jrv250013r54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2024.2346819","article-title":"Management of acute non-infectious anterior uveitis in adults\u2014practice patterns among uveitis specialists in North America.","author":"Zhang","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"jrv250013r55","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/0039-6257(86)90077-9","article-title":"Corticosteroid-induced cataracts.","volume":"31","author":"Urban","year":"1986","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"jrv250013r56","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1177\/1120672119899379","article-title":"Risk factors for ocular complications in adult patients with uveitis.","volume":"30","author":"Prieto-Del-Cura","year":"2020","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"jrv250013r57","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/09273948.2011.646382","article-title":"High-dose intravenous corticosteroids for ocular inflammatory diseases.","volume":"20","author":"Charkoudian","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"issue":"10","key":"jrv250013r58","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.ophtha.2015.06.042","article-title":"Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-month results of the Multicenter Uveitis Steroid Treatment (MUST) trial and follow-up study.","volume":"122","author":"Kempen","year":"2015","journal-title":"Ophthalmology"},{"issue":"10","key":"jrv250013r59","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment trial.","volume":"118","author":"Kempen","year":"2011","journal-title":"Ophthalmology"},{"issue":"19","key":"jrv250013r60","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2017.5103","article-title":"Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis.","volume":"317","author":"Kempen","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"jrv250013r62","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) initiative.","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"issue":"11","key":"jrv250013r63","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases.","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"issue":"3","key":"jrv250013r64","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation.","volume":"149","author":"Daniel","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"jrv250013r65","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/bjophthalmol-2017-310156","article-title":"Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial.","volume":"102","author":"Deuter","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"jrv250013r66","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome.","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv250013r67","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases.","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"jrv250013r68","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":"Cyclosporine for ocular inflammatory diseases.","volume":"117","author":"Ka\u00e7maz","year":"2010","journal-title":"Ophthalmology"},{"issue":"2","key":"jrv250013r69","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10384-021-00878-w","article-title":"Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt-Koyanagi-Harada disease.","volume":"66","author":"Ono","year":"2022","journal-title":"Jpn J Ophthalmol"},{"issue":"10","key":"jrv250013r70","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis.","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"10050","key":"jrv250013r71","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"17","key":"jrv250013r72","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis.","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv250013r73","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.","volume":"77","author":"Quartier","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"jrv250013r74","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3899\/jrheum.180312","article-title":"Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab\u2014the GO-EASY study.","volume":"46","author":"van Bentum","year":"2019","journal-title":"J Rheumatol"},{"key":"jrv250013r75","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211003803","article-title":"Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study.","volume":"13","author":"van der Horst-Bruinsma","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"7","key":"jrv250013r76","first-page":"2678","article-title":"A phase 2 randomized controlled trial of the Janus Kinase (JAK) inhibitor filgotinib in patients with noninfectious uveitis.","volume":"63","author":"Srivastava","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"jrv250013r77","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","article-title":"Filgotinib in active noninfectious uveitis: the HUMBOLDT randomized clinical trial.","volume":"142","author":"Srivastava","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"jrv250013r78","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/09273948.2013.866256","article-title":"Viral retinitis following intraocular or periocular corticosteroid administration: a case series and comprehensive review of the literature.","volume":"22","author":"Takakura","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"jrv250013r79","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0002-9394(03)00896-1","article-title":"Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases.","volume":"137","author":"Benz","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"jrv250013r80","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ophtha.2020.01.008","article-title":"Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis\u2014Report 1: guidelines for initiating antitubercular therapy in tubercular choroiditis.","volume":"128","author":"Agrawal","year":"2021","journal-title":"Ophthalmology"},{"issue":"2","key":"jrv250013r81","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.survophthal.2022.10.001","article-title":"Anti-tubercular therapy in the treatment of tubercular uveitis: a systematic review and meta-analysis.","volume":"68","author":"Betzler","year":"2023","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"jrv250013r83","doi-asserted-by":"publisher","first-page":"124","DOI":"10.14744\/eer.2022.57966","article-title":"Ocular syphilis.","volume":"2","author":"Ozdemir Yalcinsoy","year":"2022","journal-title":"Eur Eye Res"},{"issue":"4","key":"jrv250013r85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021.","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"jrv250013r86","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6594849","article-title":"Clinical features and treatments of syphilitic uveitis: a systematic review and meta-analysis.","volume":"2017","author":"Zhang","year":"2017","journal-title":"J Ophthalmol"},{"issue":"1","key":"jrv250013r87","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41433-023-02630-9","article-title":"The Infectious Uveitis Treatment Algorithm Network (TITAN) Report 1\u2014global current practice patterns for the management of herpes simplex virus and varicella zoster virus anterior uveitis.","volume":"38","author":"Thng","year":"2024","journal-title":"Eye (Lond)"},{"issue":"1","key":"jrv250013r88","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41433-023-02631-8","article-title":"The Infectious Uveitis Treatment Algorithm Network (TITAN) Report 2\u2014global current practice patterns for the management of cytomegalovirus anterior uveitis.","volume":"38","author":"Thng","year":"2024","journal-title":"Eye (Lond)"},{"issue":"7","key":"jrv250013r89","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/09273948.2018.1498109","article-title":"Review for disease of the year: treatment of viral anterior uveitis: a perspective.","volume":"26","author":"Zandi","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"issue":"11","key":"jrv250013r90","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.ophtha.2024.06.003","article-title":"Risk of recurrence in acute anterior uveitis.","volume":"131","author":"Brodie","year":"2024","journal-title":"Ophthalmology"},{"issue":"3","key":"jrv250013r91","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s40135-015-0076-6","article-title":"Infectious uveitis.","volume":"3","author":"Lin","year":"2015","journal-title":"Curr Ophthalmol Rep"},{"issue":"4","key":"jrv250013r92","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.survophthal.2021.12.006","article-title":"Clinical characteristics and treatment outcomes of cytomegalovirus anterior uveitis and endotheliitis: a systematic review and meta-analysis.","volume":"67","author":"La Distia Nora","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"jrv250013r93","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/aes-21-18","article-title":"Cytomegalovirus retinitis in the highly active anti-retroviral therapy era.","volume":"7","author":"Ude","year":"2022","journal-title":"Ann Eye Sci"},{"issue":"8","key":"jrv250013r94","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jfma.2023.03.014","article-title":"Cytomegalovirus uveitis: Taiwan expert consensus.","volume":"122","author":"Chiang","year":"2023","journal-title":"J Formos Med Assoc"},{"issue":"12","key":"jrv250013r95","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1592\/phco.27.12.1711","article-title":"Candida endophthalmitis: focus on current and future antifungal treatment options.","volume":"27","author":"Khan","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"20","key":"jrv250013r96","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia.","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv250013r97","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"jrv250013r98","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jrv250013r99","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10792-021-01994-9","article-title":"Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches.","volume":"42","author":"Kalogeropoulos","year":"2022","journal-title":"Int Ophthalmol"},{"issue":"5","key":"jrv250013r100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002218.pub2","article-title":"Antibiotics versus no treatment for toxoplasma retinochoroiditis.","volume":"2016","author":"Pradhan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"jrv250013r101","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13643-021-01758-7","article-title":"Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis.","volume":"10","author":"Feliciano-Alfonso","year":"2021","journal-title":"Syst Rev"},{"issue":"4","key":"jrv250013r102","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/bjo.2002.013334","article-title":"The risk of complications of uveitis in a district hospital cohort.","volume":"88","author":"Maini","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"jrv250013r103","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.2147\/OPTH.S86578","article-title":"Infectious uveitis in Virginia.","volume":"9","author":"Engelhard","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"jrv250013r104","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/09273948.2024.2382347","article-title":"Ocular syphilis\u2014clinical features and outcome in HIV positive and HIV negative patients from a tertiary eye center from India\u2014a comparative study.","volume":"33","author":"Ahmed","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"jrv250013r105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012232","article-title":"Clinical characteristics, visual acuity outcomes, and factors associated with loss of vision among patients with active ocular toxoplasmosis: a retrospective study in a Thai tertiary center.","volume":"18","author":"Sittivarakul","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"jrv250013r106","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ophtha.2020.08.035","article-title":"Seven-year outcomes of uveitic macular edema: the Multicenter Uveitis Steroid Treatment trial and follow-up study results.","volume":"128","author":"Tomkins-Netzer","year":"2021","journal-title":"Ophthalmology"},{"issue":"6","key":"jrv250013r107","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.ophtha.2020.10.036","article-title":"Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis.","volume":"128","author":"Suhler","year":"2021","journal-title":"Ophthalmology"},{"key":"jrv250013r61","unstructured":"National Institute for Health and Care Excellence. Adalimumab and dexamethasone for treating non-infectious uveitis. Published July 26, 2017. Accessed January 1, 2024. https:\/\/www.nice.org.uk\/guidance\/ta460\/chapter\/1-Recommendations"},{"key":"jrv250013r82","unstructured":"World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis. Published 2017. Accessed April 3, 2025. https:\/\/www.who.int"},{"key":"jrv250013r84","unstructured":"World Health Organization. WHO guidelines for the treatment of Treponema pallidum (syphilis). Published 2016. Accessed April 3, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789241549714"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2834628\/jama_maghsoudlou_2025_rv_250013_1753377741.58.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:00:43Z","timestamp":1754406043000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2834628"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.4358","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,5]]}}}